Article Sidebar

PDF
Date Published: 24/07/2021
Abstract Views: 478
Views PDF: 201
DOI: https://doi.org/10.51298/vmj.v502i1.542
Issue
Vol. 502 No. 1 (2021)
Section
Các bài báo
How to Cite
Thùy Linh, D. ., Thị Mai, P. ., Văn Tôn, T. ., Thị Định, L. ., Văn Ba, N. ., & Viết Tiến, T. . (2021). RESULTS OF INTENSITY MODULAED RADIATION THERAPY TECHNIQUE COMBINE WITH CHEMOTHERAPY FOLFOX FOR ESOPHAGEAL CANCER PATIENTS. Vietnam Medical Journal, 502(1). https://doi.org/10.51298/vmj.v502i1.542

RESULTS OF INTENSITY MODULAED RADIATION THERAPY TECHNIQUE COMBINE WITH CHEMOTHERAPY FOLFOX FOR ESOPHAGEAL CANCER PATIENTS

Dương Thùy Linh, Phạm Thị Mai, Trần Văn Tôn, Lại Thị Định, Nguyễn Văn Ba, Trần Viết Tiến

Main Article Content

Abstract

Background: This study aims to evaluate some patient’s characteristics and treatment outcome of concurrent chemoradiation therapy with intensity modulated radiation therapy (IMRT) technique in esophageal cancer patients. Materials and methods: A descriptive perspective study with 32esophageal cancer patients treated by concurrent chemoradiation therapy with IMRT using simultanous intergrated technique in Department of Radiation oncology, Oncology Center, 103 Military Hospital from 2018 to June 2020. Result: Disease are most seen in men, age 40 – 59 years old. Most of patients are late stage with 100% histopathology is squamous cell cancer in moderately differentiation acounted for 50%. Radiation schedules were 66Gy/30fx and 60Gy/28fx in 25% and 75%, respectively. Chemo regimens were Oxaliplatin 85mg/m2 day 1, Leucovorin 400mg/m2 day 1 and Fluorouracil 400mg/m2 bolus day 1, Fluorouracil 1600mg/m2, 46 hous, every 14 days.Full dose chemotherapy was given in 71,9%. Common toxicities were low hematological toxicity, esophagitis (90,6%) and dermatis (56,2%). Most of them were grade 1,2. Conclusions: Concurrent chemoradiation with IMRT technique and FOLFOX in esophageal cancer patient had promising results and well tolerence.

Article Details

Keywords

intensity modulated radiation therapy, concurrent chemoradiotherapy, Esophageal cancer

References

1. Freddie Bray, Jacques Ferlay, Isabelle SorJomataram et al (2018), Global Cancer Statistics 2018: GLOBOCAN Estimatesof Incidence and Mortality Worldwide for 36 Cancersin 185 Countries; CA Cancer J Clin 2018; 25-31.
2. Honing J, Smit JK, Muijs CT et al (2014). A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol. 25(3): 638-43
3. Conroy T, Galais MP, Raoul JL, et al (2014).Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol . 15:305-314.
4. Clinical Practice Guidelines in Oncology (2015). Esophageal and Esophagogastric Junction cancers. NCCN Guidelines version 3.2015. 51.
5. Haefner et al (2017). Intensity - modulated versus 3 – dimensional conformal radiotherapy in the definitive treatment of esophageal cancer: comparison of outcomes and acute toxicity. Radiation Oncology. 2017; 12:13.
6. Makoto Ito, Takeshi Kodaira, Hiroyuki Tachibama et al (2017).Clinical results of definitive chemoradiotherapy for cervical esophageal cancer: Comparison of failure pattern and toxicities between intensity - modulated radiotherapy and 3 - dimensional conformal radiotherapy. Head neck.2017 Dec;39(12):2406-2415
7. Galais MP Conroy T, Raoul JL et al. (2014), Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patient with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial, Lancet Oncology, 15, tr. 305-314.
8. Nguyễn Đức Lợi (2015) Đánh giá hiệu quả phác đồ hóa xạ trị đồng thời và một số yếu tố tiên lượng ung thư biểu mô thực quản giai đoạn III, IV tại bệnh viện K, Luận án tiến sĩ y khoa, Đại học Y HN.